WHO's essential medicines and AWaRe : recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections
Moja, Lorenzo; Zanichelli, Veronica; Mertz, Dominik; Gandra, Sumanth; Cappello, Bernadette; Cooke, Graham S.; Chuki, Pem; Harbarth, Stephan; Pulcini, Celine; Mendelson, Marc; Tacconelli, Evelina; Ombajo, Loice Achieng; Chitatanga, Ronald; Zeng, Mei; Imi, Monica; Elias, Christelle; Ashorn, Per; Marata, Annamaria; Paulin, Sarah; Muller, Arno; Aidara-Kane, Awa; Wi, Teodora Elvira; Were, Wilson Milton; Tayler, Elizabeth; Figueras, Albert; Da Silva, Carmem Pessoa; Van Weezenbeek, Catharina; Magrini, Nicola; Sharland, Mike; Huttner, Benedikt; Loeb, Mark (2024-04)
Moja, Lorenzo
Zanichelli, Veronica
Mertz, Dominik
Gandra, Sumanth
Cappello, Bernadette
Cooke, Graham S.
Chuki, Pem
Harbarth, Stephan
Pulcini, Celine
Mendelson, Marc
Tacconelli, Evelina
Ombajo, Loice Achieng
Chitatanga, Ronald
Zeng, Mei
Imi, Monica
Elias, Christelle
Ashorn, Per
Marata, Annamaria
Paulin, Sarah
Muller, Arno
Aidara-Kane, Awa
Wi, Teodora Elvira
Were, Wilson Milton
Tayler, Elizabeth
Figueras, Albert
Da Silva, Carmem Pessoa
Van Weezenbeek, Catharina
Magrini, Nicola
Sharland, Mike
Huttner, Benedikt
Loeb, Mark
04 / 2024
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202405145824
https://urn.fi/URN:NBN:fi:tuni-202405145824
Kuvaus
Peer reviewed
Tiivistelmä
The WHO Model List of Essential Medicines (EML) prioritizes medicines that have significant global public health value. The EML can also deliver important messages on appropriate medicine use. Since 2017, in response to the growing challenge of antimicrobial resistance, antibiotics on the EML have been reviewed and categorized into three groups: Access, Watch, and Reserve, leading to a new categorization called AWaRe. These categories were developed taking into account the impact of different antibiotics and classes on antimicrobial resistance and the implications for their appropriate use. The 2023 AWaRe classification provides empirical guidance on 41 essential antibiotics for over 30 clinical infections targeting both the primary health care and hospital facility setting. A further 257 antibiotics not included on the EML have been allocated an AWaRe group for stewardship and monitoring purposes. This article describes the development of AWaRe, focussing on the clinical evidence base that guided the selection of Access, Watch, or Reserve antibiotics as first and second choices for each infection. The overarching objective was to offer a tool for optimizing the quality of global antibiotic prescribing and reduce inappropriate use by encouraging the use of Access antibiotics (or no antibiotics) where appropriate. This clinical evidence evaluation and subsequent EML recommendations are the basis for the AWaRe antibiotic book and related smartphone applications. By providing guidance on antibiotic prioritization, AWaRe aims to facilitate the revision of national lists of essential medicines, update national prescribing guidelines, and supervise antibiotic use. Adherence to AWaRe would extend the effectiveness of current antibiotics while helping countries expand access to these life-saving medicines for the benefit of current and future patients, health professionals, and the environment.
Kokoelmat
- TUNICRIS-julkaisut [19214]